11 – 20 of 26
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Arandomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
(
- Contribution to journal › Article
-
Mark
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
- 2008
-
Mark
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
(
- Contribution to journal › Article
- 2007
-
Mark
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
The APC-PCI complex concentration predicts outcome of aortic surgery.
(
- Contribution to journal › Article
- 2005
-
Mark
Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival.
(
- Contribution to journal › Article
- 2003
-
Mark
Monitoring the bioavailability of FEIBA with a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Thrombosis in inherited factor VII deficiency.
(
- Contribution to journal › Article
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
(
- Contribution to journal › Article